{
    "nct_id": "NCT05561205",
    "title": "Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)",
    "status": "RECRUITING",
    "last_update_time": "2025-07-02",
    "description_brief": "Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "methylphenidate"
    ],
    "placebo": [
        "sham rTMS"
    ],
    "explanation_target": [
        "Reason: The trial tests repetitive transcranial magnetic stimulation (rTMS) as a treatment for apathy (a behavioural/neuropsychiatric symptom) in people with dementia/Alzheimer\u2019s disease; the description explicitly compares rTMS effects in individuals receiving methylphenidate versus those not on apathy medication, indicating the primary goal is symptom (apathy) improvement rather than disease modification. \ue200cite\ue202turn0search7\ue202turn0search8\ue201",
        "Act: Key extracted details \u2014 intervention: rTMS (device/neuromodulation) and concomitant medication methylphenidate (a small\u2011molecule CNS stimulant that blocks dopamine and norepinephrine reuptake). The trial listing (NCT05561205 / REACT) names rTMS as the device intervention and methylphenidate as the medication of interest; rTMS trials for apathy are commonly sham\u2011controlled (sham rTMS). The pharmacology/mechanism for methylphenidate (NDRI/CNS stimulant) is summarized in regulatory and clinical sources. \ue200cite\ue202turn0search8\ue202turn1search1\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 this fits the 'neuropsychiatric symptom improvement' category because (1) the target symptom is apathy (a neuropsychiatric/behavioral symptom), (2) neither intervention is described as targeting core AD pathology (amyloid/tau) or as a disease\u2011modifying biologic/small molecule, and (3) the intended effect is symptomatic improvement of motivation/engagement rather than broad cognitive enhancement or disease modification. Note ambiguity: methylphenidate appears as a concomitant/stratifying medication rather than necessarily the investigational randomized drug in this pilot rTMS study; sham rTMS is the likely control. \ue200cite\ue202turn0search7\ue202turn0search3\ue201",
        "Web search results used (short notes): REACT / RTMS for Apathy trial listing (NCT05561205) \u2014 describes rTMS and methylphenidate in the study. \ue200cite\ue202turn0search8\ue201; Toronto Dementia Network REACT summary \u2014 trial purpose and design summary referencing rTMS and methylphenidate. \ue200cite\ue202turn0search7\ue201; ADMET\u20112 methylphenidate trial (shows methylphenidate has been tested for apathy in AD). \ue200cite\ue202turn0search6\ue201; rTMS pilot/RCTs for apathy and neuromodulation literature (rTMS used to treat apathy/depression in MCI/AD). \ue200cite\ue202turn0search0\ue202turn0search3\ue201; Methylphenidate pharmacology/mechanism (blocks reuptake of norepinephrine and dopamine; CNS stimulant). \ue200cite\ue202turn1search1\ue202turn1search4\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial includes methylphenidate, which exerts its effects by blocking dopamine and norepinephrine reuptake (acting on DAT and NET) and thereby modulates monoaminergic neurotransmission \u2014 this maps to a neurotransmitter system/target. The study also uses rTMS (a neuromodulation device) for apathy, but the drug's molecular target is the monoamine transporters, so the drug target classification is neurotransmitter-related. \ue200cite\ue202turn0search0\ue201",
        "Act: Key extracted details \u2014 drug: methylphenidate (a CNS stimulant; norepinephrine\u2013dopamine reuptake inhibitor acting at DAT and NET). Trial intervention includes rTMS (device) and methylphenidate (drug); because the requested classification is for the drug target, assign CADRO category D) Neurotransmitter Receptors. \ue200cite\ue202turn0search0\ue202turn2search0\ue201",
        "Reflect: Confirming fit \u2014 methylphenidate's mechanism (DAT/NET inhibition) is a direct modulation of neurotransmitter systems and fits CADRO category D. Note: rTMS works via network/plasticity and can increase dopamine release (which relates to neurotransmission and could also be viewed as neuromodulation/synaptic plasticity), but since the drug target is clearly monoaminergic transporters, D is the most specific CADRO match for the drug. If the goal were to classify the device intervention or the combined device+drug mechanism, one could consider R) Multi-target or M) Synaptic Plasticity, but for the drug itself D is correct. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Web search results used (short notes): 1) Methylphenidate mechanism \u2014 blocks reuptake of norepinephrine and dopamine (DAT/NET). \ue200cite\ue202turn0search0\ue201; 2) rTMS for apathy \u2014 rTMS is a neuromodulation intervention that can increase cortical dopamine release and induce synaptic plasticity; used for apathy in AD/MCI. \ue200cite\ue202turn0search6\ue202turn0search2\ue201; 3) Trial listing (REACT, NCT05561205) \u2014 confirms interventions are device: rTMS and drug: methylphenidate and that the study targets apathy in neurocognitive disorders. \ue200cite\ue202turn2search0\ue201"
    ]
}